Boehringer makes an ADC deal with AimedBio; EyePoint’s $150M stock salenews2025-10-15T14:38:15+00:00October 15th, 2025|Endpoints News|
FDA delays decision on Denali drug; Astellas’ Vyloy fails mid-stage pancreatic cancer trialnews2025-10-14T14:40:28+00:00October 14th, 2025|Endpoints News|
SystImmune’s $250M milestone; Teva’s Uzedy approved to treat bipolar disordernews2025-10-13T14:54:01+00:00October 13th, 2025|Endpoints News|
Satellos to run a trial for Duchenne pill in kids; Idorsia raises $81Mnews2025-10-10T14:16:48+00:00October 10th, 2025|Endpoints News|
AviadoBio, UgeneX Therapeutics ink up to $413M deal; Apogee’s $300M stock salenews2025-10-09T15:19:02+00:00October 9th, 2025|Endpoints News|
Shanghai biotech claims Phase 2 win in endometriosis; Karyopharm’s $100Mnews2025-10-08T14:40:41+00:00October 8th, 2025|Endpoints News|
Adicet reveals Phase 1 data for lupus therapy; Arcus’ ‘best-in-class’ kidney cancer drugnews2025-10-07T14:16:05+00:00October 7th, 2025|Endpoints News|
NanoPhoria’s €83M Series A; AstraZeneca makes deal worth up to $555M with Algennews2025-10-06T14:29:40+00:00October 6th, 2025|Endpoints News|
FDA OKs Zepzelca-Tecentriq combo; CSL Vifor’s layoffsnews2025-10-03T15:07:31+00:00October 3rd, 2025|Endpoints News|
Taysha may file for approval sooner than expected; Metagenomi ends work with Affini-Tnews2025-10-02T15:14:24+00:00October 2nd, 2025|Endpoints News|
